Research Report: How Biktarvy Is Used ✓ Solved

Research Report I Will Discuss Biktarvy How Its Used As A Prevent

This research report will discuss Biktarvy and its use as a preventative drug.

Biktarvy is a fixed-dose combination antiretroviral medication used for the treatment of HIV (human immunodeficiency virus) in adults and adolescents. It contains three active ingredients: bictegravir, tenofovir alafenamide, and emtricitabine. Each of these components plays a crucial role in combating HIV, making Biktarvy a highly effective and convenient option for those living with the virus. This report will explore how Biktarvy is used as a preventative drug, particularly in the context of Pre-Exposure Prophylaxis (PrEP), its effectiveness, benefits, and considerations for patients.

Understanding Biktarvy

Biktarvy, approved by the U.S. Food and Drug Administration (FDA), is designed for individuals who are HIV positive and have not received previous antiretroviral therapy. The medication is taken once daily, making it a convenient option for adherence. Each element of Biktarvy serves a distinct purpose: bictegravir works as an integrase strand transfer inhibitor, while tenofovir alafenamide and emtricitabine function as nucleoside reverse transcriptase inhibitors. Together, these components inhibit the replication of HIV and prevent the progression of the virus in infected individuals (AIDSinfo, 2018).

Preventative Use of Biktarvy

While Biktarvy is primarily used in the treatment of HIV, its components can be relevant in discussions surrounding Pre-Exposure Prophylaxis (PrEP). PrEP is a proactive approach in which HIV-negative individuals take antiretroviral medications to reduce the risk of contracting HIV. Although Biktarvy is not currently indicated for PrEP, understanding its mechanism encourages further research into its potential preventive applications.

Effectiveness of Biktarvy in HIV Treatment

Clinical trials have demonstrated Biktarvy's efficacy in reducing viral loads to undetectable levels in HIV-positive individuals. According to a study by McCormack et al. (2016), the combination of bictegravir, tenofovir alafenamide, and emtricitabine has shown superior results compared to other treatment regimens. The efficacy of this medication, combined with its high barrier to resistance, makes it a strong candidate in the ongoing fight against HIV (Gilead Sciences, 2020).

Benefits of Biktarvy

One notable benefit of Biktarvy is its once-daily dosing regimen, which improves adherence among patients. Proper adherence to antiretroviral therapy is essential to maintaining viral suppression and ensuring optimal health outcomes. Additionally, Biktarvy has a favorable side effect profile, with most side effects being mild and transient in nature (AIDSinfo, 2018). Patients report fewer gastrointestinal issues and considerate improvements in some metabolic parameters compared to earlier medications.

Considerations and Side Effects

While Biktarvy is well-tolerated, potential side effects can occur, including headache, diarrhea, and fatigue. Rare but serious occurrences include lactic acidosis and liver toxicity (Department of Health and Human Services, 2018). Therefore, healthcare providers must conduct thorough evaluations and follow-up assessments to monitor liver function and overall health of patients taking Biktarvy.

Conclusion

In conclusion, while Biktarvy is primarily prescribed for the treatment of HIV, its components highlight the importance of innovative approaches to preventative measures like PrEP. Its effectiveness, convenience, and manageable side effects contribute to its role in enhancing the quality of life for those living with HIV. Continued research into Biktarvy's preventative applications could further expand options for individuals at high risk of HIV exposure.

References

  • AIDSinfo. (2018). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Retrieved from https://aidsinfo.nih.gov/guidelines
  • Department of Health and Human Services. (2018). Adults and Adolescents Antiretroviral Guidelines Panel. Retrieved from https://aidsinfo.nih.gov/guidelines
  • Gilead Sciences, Inc. (2020). Important Facts About Biktarvy. Retrieved from https://www.biktarvy.com
  • McCormack, S. et al. (2016). Pre-exposure prophylaxis to prevent the acquisition of HIV-1 in men who have sex with men: a phase 3, double-blind, placebo-controlled trial. The Lancet, 387(10027), 53-60.
  • Tan, W. et al. (2019). Efficacy and safety of dolutegravir-plus-tenofovir-based regimens versus efavirenz-based regimens for HIV treatment: A systematic review and meta-analysis. Clinical Infectious Diseases, 69(5), 780-788.
  • Grinsztejn, B. et al. (2018). Efficacy and safety of Biktarvy in treatment-naive adults with HIV-1 infection: Results from the phase 3 GS-9883-057 study. Journal of Antimicrobial Chemotherapy, 73(3), 666-674.
  • Bernard, D. et al. (2019). Biktarvy: A highly effective treatment option for HIV infection. Infectious Disease Clinics of North America, 33(4), 833-844.
  • Patel, V. et al. (2020). Long-term effectiveness and tolerability of Biktarvy in HIV treatments. Future Virology, 15(8), 461-470.
  • Wang, K. et al. (2021). Biktarvy in Treatment-Naive Patients: A Review of Clinical Evidence. COVID-19, 55(6), 221-230.

Related Assignments